Hyderabad, March 24: Suven Life Sciences Ltd has been granted two product patents in Eurasia for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents (nos. 009193 and 009367) are valid till 2023 in all contracting countries such as Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan.
“We are very pleased by the grant of these patents to Suven for our drug candidates that are being developed for CNS disorders, which target an $18 billion potential market opportunity globally,” Mr Venkat Jasti, Chief Executive Officer of Hyderabad-based Suven Life Sciences, said in a release. Products out of these inventions, which were in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
They would be useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as attention deficient hyperactivity, Alzheimer’s, Parkinson’s, schizophrenia and Huntington’s, the release added.